Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

YB-1113 · UMC-119-06, UMC119-01

Cell therapy (Stem-cell derived) · developed by Bright Cell

Phase 1 Most advanced trial

DRUG Developer

1 Registered trials

What is YB-1113?

YB-1113 is a cell therapy composed of human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC). It is being studied in premature ovarian insufficiency (POI).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: UMC-119-06, UMC119-01
Drug type: Cell therapy (Stem-cell derived)
Therapy area: Endocrine
Developer: Bright Cell, Inc. (DRUG)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: G64F59W88V

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05494723	Phase 1	POI	Not yet recruiting	DRUG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

POI

More from Bright Cell

BC-101 Phase 1 BMB-101 Phase 2 BPT567 Phase 1

Sources

ClinicalTrials.gov NCT05494723

Updated Oct 3, 2026. Something wrong or missing? Report it on the DRUG page.

Follow DRUG, the company behind YB-1113

See DRUG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DRUG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z